Enjoy complimentary customisation on priority with our Enterprise License!
The orthostatic hypotension drugs market share is expected to increase by USD 571.76 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 9.06%.
This orthostatic hypotension drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers orthostatic hypotension drugs market segmentations by product (midodrine, northera (droxidopa), fludrocortisone, and other drugs) and geography (North America, Europe, Asia, and Rest of World (ROW)). The orthostatic hypotension drugs market report also offers information on several market vendors, including Alchemy Laboratories Pvt Ltd., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Apotex Inc., Avadel Pharmaceuticals plc, Baxter International Inc., Brancaster Pharma Ltd., Cadila Healthcare Ltd., Cerecor Inc., Enaltec Labs Pvt. Ltd., Endo International Plc, H. Lundbeck AS, Hikma Pharmaceuticals Plc, J B Chemicals and Pharmaceuticals Ltd., Manus Aktteva Biopharma LLP, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Theravance Biopharma Inc., and Viatris Inc. among others.
Download the Free Report Sample to Unlock the Orthostatic Hypotension Drugs Market Size for the Forecast Period and Other Important Statistics
The increasing prevalence of OH in the geriatric population is notably driving the orthostatic hypotension drugs market growth, although factors such as the low diagnosis rate of oh may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the orthostatic hypotension drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Orthostatic Hypotension Drugs Market Driver
The increasing prevalence of OH in the geriatric population is one of the key drivers supporting the orthostatic hypotension drugs market growth. OH is a common condition in geriatric patients and is associated with significant morbidity and mortality. The geriatric population is prone to chronic diseases that require polypharmacy for treatment, one of the major risk factors of OH. Moreover, the geriatric population often requires hospital admissions due to illness or injuries. The bedrest confinement during hospitalization may lead to physiological deconditioning, functional decline, and OH. In addition, barosensory vessel wall stiffness increases with age while cardio-vagal autonomic control effectiveness decreases, which raises the risk of it. These factors are expected to drive the demand for OH treatment, which will contribute to the growth of the global OH drugs market during the forecast period.
Key Orthostatic Hypotension Drugs Market Trend
Research and Development of new drugs for OH treatment is one of the key orthostatic hypotension drugs market trends that is contributing to the market growth. There is a high unmet need for drugs in the OH drugs market due to a lack of approval with substantial clinical efficiency and high safety profile. Hence, there is an increasing focus on R and D of novel drugs to cater to the unmet need in OH pharmacological therapy. For instance, Lundbeck LLC conducted Phase 5 clinical trials (post-marketing study) in the US to assess the sustained effects of droxidopa therapy in patients with nOH. The study was completed in December 2020 and Theravance Biopharma Inc. announced the positive topline four-week data from the Phase 2 clinical trial of ampreloxetine for the treatment of symptomatic nOH. These initiatives are expected to boost the market growth during the forecast period.
Key Orthostatic Hypotension Drugs Market Challenge
The low diagnosis rate of OH is one of the factors hindering the orthostatic hypotension drugs market growth. Though OH is common in the geriatric population and is associated with substantial morbidity and variable prognosis, its diagnosis rate is low. This is because OH remains asymptomatic in most cases. In general, patients do not initiate a discussion about their nOH symptoms with their healthcare providers unless the symptoms are severe. Hence, it is difficult to manage OH in patients with several complex medical issues such as PD that are challenging to manage. Patients often hide or minimize their nOH symptoms as they view symptoms as a sign of weakness or because they are embarrassed. Furthermore, most patients are unaware that nOH can be associated with PD. Hence, the lack of diagnosis of nOH results in a delay in the treatment of OH, which may restrict the market uptake of OH drugs.
This orthostatic hypotension drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global orthostatic hypotension (OH) drugs market as a part of the pharmaceutical market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the orthostatic hypotension drugs market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the orthostatic hypotension drugs market encompasses successful business strategies deployed by the key vendors. The orthostatic hypotension drugs market is fragmented and the vendors are deploying growth strategies such as expanding their product portfolios by investing in R and D to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The orthostatic hypotension drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the orthostatic hypotension drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request for a FREE sample now!
42% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for the orthostatic hypotension drugs market in North America. Market growth in this region will be faster than the growth of the market in ROW.
The high per capita pharmaceutical expenditure will facilitate the orthostatic hypotension drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The COVID-19 pandemic had a positive impact on the OH drugs market in North America in 2020. Moreover, North America is projected to account for the major share of the global OH drugs market during the forecast period due to its well-established healthcare infrastructure and presence of key players in the market.
To gain further insights on the market contribution of various segments Request for a FREE sample
The orthostatic hypotension drugs market share growth by the midodrine segment will be significant during the forecast period. Midodrine is a pro-drug that rapidly converts to its active metabolite desglymidodrine, which is a selective alpha1-adrenergic agonist that increases blood pressure by inducing vasoconstriction. It is the first drug that was approved in the US for the treatment of OH in 1996, under the FDA accelerated approval regulation for medications for the treatment of serious or life-threatening diseases. It is also approved for the treatment of OH in some European countries, such as Germany, France, and the UK. Such increasing approval will drive the segment growth during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the orthostatic hypotension drugs market size and actionable market insights on post COVID-19 impact on each segment.
|
Orthostatic Hypotension Drugs Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2021 |
|
Forecast period |
2022-2026 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 9.06% |
|
Market growth 2022-2026 |
$ 571.76 million |
|
Market structure |
Fragmented |
|
YoY growth (%) |
6.44 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 42% |
|
Key consumer countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
Alchemy Laboratories Pvt Ltd., Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Apotex Inc., Avadel Pharmaceuticals plc, Baxter International Inc., Brancaster Pharma Ltd., Cadila Healthcare Ltd., Cerecor Inc., Enaltec Labs Pvt. Ltd., Endo International Plc, H. Lundbeck AS, Hikma Pharmaceuticals Plc, J B Chemicals and Pharmaceuticals Ltd., Manus Aktteva Biopharma LLP, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Theravance Biopharma Inc., and Viatris Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Product
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Customized Report as per your Business Needs
Let us help you make report more suited to your requirements.
Get the report (PDF) sent to your email within minutes.
